TRIVARIS
LOE ApproachingNDAINTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREALINJECTABLE
Approved
Jun 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIVARIS is a small-molecule injectable approved in 2008 by AbbVie, administered via intra-articular, intramuscular, or intravitreal routes. The mechanism of action and specific indications are not publicly disclosed in available data. The product targets localized tissue pathology requiring direct injection into affected sites.
LOE Approaching
Product is entering late-stage lifecycle with moderate competitive pressure (30%), signaling potential downsizing or transition of commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRIVARIS currently has zero linked job openings, reflecting its mature lifecycle stage approaching LOE. Roles on this product are primarily defensive—focused on maintaining market share and managing the transition to generic competition rather than growth.
Brand ManagerField Sales Representative
Worked on TRIVARIS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.